Products Categories
| CAS No.: | 90357-06-5 |
|---|---|
| Name: | Bicalutamide |
| Article Data: | 51 |
| Molecular Structure: | |
|
|
|
| Formula: | C18H14F4N2O4S |
| Molecular Weight: | 430.38 |
| Synonyms: | (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfonyl-2-hydroxy-2-methyl-propanamide;Casodex;Propanamide, N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-hydroxy-2-methyl-, (+-)-;Bicalutamide (JAN/USP);Casodex (TN);(±)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-methyl-[(4- fluorophenyl) sulfonyl]-2-hydroxy- 2-methyl propanamide;N-(4-cyano-3-(trifluoromethyl)phenyl)-3-(4-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide;Bicalutamide [USAN:BAN:INN];ICI 176334;Propanamide,N-[4-cyano-3-(trifluoromethyl)- phenyl]-3-[(4-fluorophenyl)sulfonyl]-2- hydroxy-2-methyl-; |
| Density: | 1.52 g/cm3 |
| Melting Point: | 191-193 °C |
| Boiling Point: | 650.3 °C at 760 mmHg |
| Flash Point: | 347.1 °C |
| Solubility: | Insoluble in water |
| Appearance: | off-white crystalline solid |
| Hazard Symbols: |
 Xi
|
| Risk Codes: | 36/37/38 |
| Safety: | 26-36 |
| PSA: | 115.64000 |
| LogP: | 4.03338 |
- 958254-66-51H-Imidazo[4,5-b]pyridine-2-carboxaldehyde, 1-methyl-, hydrochloride
- 99170-93-1N-Methyl-2-oxazolamine
- 914458-26-7[5-(2-fluorophenyl)-1-pentyl-1H-pyrrol-3-yl]-1-naphthalenyl-Methanone
- 97730-31-9(S)-4'-(2-Methylbutyl)Biphenyl-4-Carbonitrile
- 926293-55-26-Bromo-2-methylpyridine-3-carboxaldehyde
- 911112-05-55-Iodo-3-(trifluoromethyl)-2-pyridinamine
- 95789-13-21,3,7-trimethylpurine-2,6-dione
- 956104-42-02-Bromo-5-nitro-3-(trifluoromethyl)pyridine
- 910247-97-11,2,3-Trimethylimidazolium dimethyl phosphate
- 945683-37-41-butyl-2,3-dimethylimidazolium octanesulfate
- 90356-78-8
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| Stage #1: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide With potassium permanganate; tetra(n-butyl)ammonium hydrogensulfate In water; ethyl acetate at 25 - 30℃; for 2.5h; Stage #2: With sodium metabisulfite In water; ethyl acetate for 1h; | 100% |
| With (dimethyl dioctadecylammonium)3[PW12O40]; dihydrogen peroxide In dichloromethane at 25℃; for 0.416667h; Catalytic behavior; Temperature; Reagent/catalyst; | 99.1% |
| Stage #1: N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide With dihydrogen peroxide; sodium tungstate; methanesulfonic acid In water; ethyl acetate at 25 - 32℃; for 6h; Stage #2: With sodium thiosulfate In water; ethyl acetate for 0.5h; Product distribution / selectivity; | 98% |
- 371-42-6
4-Fluorothiophenol
- 90357-51-0
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| Stage #1: 4-Fluorothiophenol; N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide With sodium hydroxide; tetra(n-butyl)ammonium hydrogensulfate In water; ethyl acetate at 25 - 30℃; for 3h; Stage #2: With potassium permanganate In water; ethyl acetate for 2.5h; Stage #3: With sodium metabisulfite In water; ethyl acetate at 50℃; for 1h; Product distribution / selectivity; | 97.3% |
- 90356-78-8
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide
A
- 945419-64-7
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-(4-fluorophenyl)sulfinyl-2-hydroxy-2-methyl-propanamide
B
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| With urea hydrogen peroxide adduct In tetrahydrofuran; formic acid; water at 27 - 35℃; for 1h; | A 0.08 %Chromat. B 96% |
- 455-15-2
1-(methylsufonyl)-4-fluorobenzene
- 87310-69-8
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-oxo propanamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| Stage #1: 1-(methylsufonyl)-4-fluorobenzene With n-butyllithium In tetrahydrofuran at -78℃; for 0.333333h; Stage #2: N-(4-cyano-3-trifluoromethyl-phenyl)-2-oxo-propionamide In tetrahydrofuran at -78 - 20℃; Further stages.; | 95% |
| Stage #1: 1-(methylsufonyl)-4-fluorobenzene With n-butyllithium In tetrahydrofuran for 1h; Stage #2: N-(4-cyano-3-trifluoromethyl-phenyl)-2-oxo-propionamide In tetrahydrofuran for 0.333333h; | 90% |
| With n-butyllithium In tetrahydrofuran | 1.67 g (90%) |
- 937-14-4
3-chloro-benzenecarboperoxoic acid
- 90356-78-8
N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfanyl]-2-hydroxy-2-methylpropanamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| In dichloromethane | 94% |
- 90357-51-0
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| With cesium fluoride In water at 90℃; for 15h; | 93% |
| With cesium fluoride In water at 90℃; for 15h; Inert atmosphere; | 93% |
- 371-42-6
4-Fluorothiophenol
- 90357-53-2
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylacrylamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| Stage #1: 4-Fluorothiophenol; N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylacrylamide With oxygen In acetonitrile at 45℃; for 10h; Stage #2: With oxone In acetonitrile for 18h; Temperature; Reagent/catalyst; | 88% |
| Stage #1: 4-Fluorothiophenol; N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methylacrylamide With oxygen In ethanol at 45℃; Green chemistry; Stage #2: With Oxone In ethanol at 45℃; Green chemistry; | 68% |
- 1067225-62-0
4-cyano-3-(trifluoromethyl)phenylisocyanide
- 432-98-4
1-(4-fluorophenylsulfonyl)propan-2-one
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| Stage #1: 4-cyano-3-(trifluoromethyl)phenylisocyanide With titanium tetrachloride In dichloromethane for 1h; Passerini reaction; Cooling with ice; Stage #2: 1-(4-fluorophenylsulfonyl)propan-2-one In dichloromethane for 3h; Passerini reaction; Stage #3: With water In dichloromethane for 0.333333h; | 66% |
- 824-80-6
sodium 4-fluorobenzenesulfinate
- 90357-51-0
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-methyloxirane-2-carboxamide
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| With tetrabutylammomium bromide In chloroform; water for 96h; Heating / reflux; | 48% |
| With sulfuric acid In ethanol for 6h; Heating / reflux; |
- 216665-25-7
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-3-iodo-2-methylpropanamide
- 824-80-6
sodium 4-fluorobenzenesulfinate
- 90357-06-5
Bicalutamide
| Conditions | Yield |
|---|---|
| In dimethyl sulfoxide at 60℃; for 8h; | 23% |
- 673-06-3D-Phenylalanine
- 123-42-24-Hydroxy-4-methyl-2-pentanone
- 102518-79-6(-)-Huperzine A
- 98-80-6Phenylboronic acid
- 590-46-5Methanaminium,1-carboxy-N,N,N-trimethyl-, chloride (1:1)
- 107868-30-46-Methyleneandrosta-1,4-diene-3,17-dione
- 624-28-22,5-Dibromopyridine
- 583-39-12-Mercaptobenzimidazole
- 104987-11-3Tacrolimus
- 141-53-7Sodium formate
- 8001-54-5Quaternary ammonium compounds, alkylbenzyldimethyl, chlorides
- 9003-39-8Povidone
- 10161-34-9Trenbolone acetate
- 402957-28-2Telaprevir
- 68-19-9Cyanocobalamin
What can I do for you?
Get Best Price
Standards and Recommendations
Bicalutamide (CAS NO.90357-06-5) is preventing the activation of the AR and acts as a pure anti-androgen by binding to the androgen receptor (AR) and subsequent upregulation of androgen responsive genes by androgenic hormones. In addition, bicalutamide accelerates the degradation of the androgen receptor.
Specification
1. Introduction of Bicalutamide
Bicalutamide is one kind of off-white crystalline solid. Bicalutamide is practically insoluble in water. The Product Categories of this chemical is Active Pharmaceutical Ingredients;Antiandrogen;Antineoplastic (Hormonal);anti-neoplastic;Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;API's. The Classification Code of Bicalutamide is Androgen antagonists; Antineoplastic; Antineoplastic agents; Drug / Therapeutic Agent; Hormone Antagonists; Hormones, Hormone Substitutes, and Hormone Antagonists; Reproductive Effect.
2. Properties of Bicalutamide
Physical properties about Bicalutamide are:
(1)XLogP3-AA: 2.3; (2)H-Bond Donor: 2; (3)H-Bond Acceptor: 9; (4)Melting Point: 191-193 °C; (5)Surface Tension: 58.2 dyne/cm; (6)Density: 1.52 g/cm3; (7)Flash Point: 347.1 °C; (8)Enthalpy of Vaporization: 100.72 kJ/mol; (9)Boiling Point: 650.3 °C at 760 mmHg; (10)Vapour Pressure: 8.47E-18 mmHg at 25°C.
3. Structure Descriptors of Bicalutamide
(1)InChI: InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)/t17-/m0/s1;
(2)InChIKey: InChIKey=LKJPYSCBVHEWIU-KRWDZBQOSA-N;
(3)Smiles: c1(c(ccc(c1)NC([C@@](CS(c1ccc(F)cc1)(=O)=O)(C)O)=O)C#N)C(F)(F)F.
4. Toxicity of Bicalutamide
| Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
|---|---|---|---|---|---|
| dog | LD | oral | > 2gm/kg (2000mg/kg) | Journal of Toxicological Sciences. Vol. 22, Pg. 75, 1997. | |
| mouse | LD | oral | > 2gm/kg (2000mg/kg) | Journal of Toxicological Sciences. Vol. 22, Pg. 75, 1997. | |
| mouse | LD50 | intraperitoneal | > 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 197, 2000. | |
| rabbit | LD50 | oral | > 200mg/kg (200mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 197, 2000. | |
| rat | LD | oral | > 2gm/kg (2000mg/kg) | Journal of Toxicological Sciences. Vol. 22, Pg. 75, 1997. | |
| rat | LD50 | intraperitoneal | > 2gm/kg (2000mg/kg) | Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 42, Pg. 197, 2000. |
5. Safety information of Bicalutamide
Bicalutamide (CAS NO.90357-06-5) is contraindicated, females and children must not be given to any patient who has shown a hypersensitivity reaction to its use.
Hazard Codes:
XiRisk Statements: 36/37/38
R36/37/38:Irritating to eyes, respiratory system and skin.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36:Wear suitable protective clothing.
RIDADR: 3077
HazardClass: 9
PackingGroup: III
6. Uses of Bicalutamide
Bicalutamide is good for the treatment of stage D2 metastatic prostate cancer in combination with a luteinizing hormone-releasing hormone analogue or as a monotherapy.It has also been used in clinical trials for ovarian cancer and in combination with castration.Most advanced prostate cancer patients eventually become resistant to antiandrogen including bicalutamide therapy. Bicalutamide is contraindicated in patients who have shown a hypersensitivity reaction to its use.
7. Production of Bicalutamide
Bicalutamide can be got from Methyl methacrylate. The detailed steps of this reaction is as follows:
